TICKERNERD
Menu
SMMTSMMTHealthcare · Biotechnology

SMMT Stock Forecast: Summit Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$13
−3.27% on the day

The 17 Wall Street analysts covering Summit Therapeutics, Inc. hold a median 12-month price target of $34 — +165.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$10.5B
Ticker Nerd rank
19 / 100
Median analyst target
$34
Analysts covering
17
Revenue$0.0
Operating income−$220.5M
Net income−$215.7M
Free cash flow−$142.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.4%
1M
−6.8%
YTD
−27.2%
1Y
−51.4%
From 52W high
−52.8%
From 52W low
+2.4%
$12
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SMMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Summit Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
83
Accruals
52
Growth
50
Revisions
37
Volatility
34
Quality
27
Issuance
26
Size
15
Momentum
15

Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SMMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SMMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40Oct 25Jan 26Apr 26Jul 26SMMTHigh $42Median $34Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
10 Buy6 Hold1 Sell
Low $10Median $34High $42

The green dot is the last close — the median target sits +165.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
18 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
12 Aug 2026Leerink PartnersUpgradeMarket Perform$12 → $13
24 July 2026GuggenheimMaintainsBuy—
24 July 2026GuggenheimMaintainsBuy$40 → $38
24 July 2026StifelMaintainsBuy—
24 July 2026StifelMaintainsBuy$45 → $38
23 July 2026HC Wainwright & Co.ReiteratesNeutral—
23 July 2026HC Wainwright & Co.ReiteratesNeutral—
22 May 2026BernsteinInitiatesUnderperform$7.70
22 May 2026BernsteinInitiatesUnderperform—
22 May 2026HC Wainwright & Co.DowngradeNeutral—
22 May 2026HC Wainwright & Co.DowngradeNeutral—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsNeutral—
8 Apr 2026StifelInitiatesBuy—
16 Mar 2026JefferiesDowngradeHold—
24 Feb 2026HC Wainwright & Co.MaintainsBuy—
2 Feb 2026HC Wainwright & Co.ReiteratesBuy—
30 Jan 2026CitizensReiteratesMarket Outperform—
17 Dec 2025BarclaysUpgradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SMMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SMMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Summit Therapeutics, Inc. returned −51.4% against +19.6% for the S&P 500, dividends included.

SMMT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26SMMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SMMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
7
Fundamentals

Summit Therapeutics, Inc. (SMMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.0×

Cheaper than 32% of US stocks

Price / sales
—
Price / book
16.6×

Cheaper than 6% of US stocks

EV / EBITDA
−11.2×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−192.5%

Higher than 7% of US stocks

Return on assets
−101.6%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Summit Therapeutics, Inc. (SMMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Summit Therapeutics, Inc. has a market value of $10.5B and an enterprise value of $9.8B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$856.0M.

  • Diluted earnings per share, trailing twelve months: $−1.12.

  • Free cash flow in the twelve months to 30 June 2026: −$459.8M, after $1.4M of capital spending.

  • Shares outstanding: 793.1M.

  • Trailing P/E: 25.0×; forward P/E: −10.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Summit Therapeutics, Inc. employs 265 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

SMMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SMMTSummit Therapeutics, Inc.$10.5B
19
CYTKCytokinetics, Inc.$10.7B
53
AXSMAxsome Therapeutics, Inc.$10.7B
74
PRAXPraxis Precision Medicines, Inc.$10.3B
43
KRYSKrystal Biotech, Inc.$10.3B
79
APGEApogee Therapeutics, Inc.$10.2B
36
KYMRKymera Therapeutics, Inc.$10.0B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Summit Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SMMT news & analysis

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Business Wire · 12 Aug 2026positive

Summit Therapeutics' partner Akeso received marketing authorization from China's NMPA for ivonescimab, a bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.

Why it matters — This regulatory approval in China advances the clinical and commercial prospects of ivonescimab, Summit's key partnered asset, in a major market.

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Barrons · 7 Aug 2026positive

A Barrons piece reports that positive readouts in cancer and cardiac drug trials could keep the rally going for biotech and pharma stocks, and it sizes up the stakes for companies including Merck, Moderna, and Summit Therapeutics. The article suggests these new drugs could fuel fresh highs.

Why it matters — Summit Therapeutics is named among the companies whose drug-trial prospects are being evaluated in the context of a broader biotech rally.

Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty

GlobeNewsWire · 6 Aug 2026negative

Lowey Dannenberg P.C. announced it is investigating whether certain officers and directors of Summit Therapeutics Inc. breached their fiduciary duties to shareholders in connection with a $520 million loan transaction between the Company and its Executive Chairman, Robert W. The investigation was announced via a press release on August 6, 2026.

Why it matters — SMMT watchers would care because the investigation raises potential governance and conflict-of-interest concerns involving a large loan between the company and its Executive Chairman.

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

Business Wire · 5 Aug 2026positive

Summit Therapeutics announced expansion of its global registration-enabling clinical development program for the investigational bispecific antibody ivonescimab into bladder cancer, or urothelial carcinoma. This includes the initiation of the global, multi-regional randomized Phase II/III HARMONi-GU1 trial, evaluating ivonescimab plus an antibody-drug conjugate in first-line bladder cancer.

Why it matters — SMMT watchers would care because it signals continued expansion of the ivonescimab clinical program into a new cancer indication with a registration-enabling Phase II/III study.

Jim Cramer Calls Summit Therapeutics A 'Great Spec,' Recommends Buying This Consumer Cyclical Stock

Benzinga · 4 Aug 2026positive

In a segment on CNBC's “Mad Money Lightning Round,” Jim Cramer called Summit Therapeutics a “Great Spec” and recommended buying auto retailer Carvana Co. on the heels of its “good” quarter.

Why it matters — SMMT watchers would care because a prominent CNBC commentator characterized the company as a high-potential speculative investment, bringing it attention in the media.

FAQ

Frequently asked questions about SMMT stock

What is the SMMT stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Summit Therapeutics, Inc. have a median 12-month price target of $34, with estimates ranging from $9.91 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SMMT stock a buy right now?

Of the 17 analysts covering Summit Therapeutics, Inc., 10 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Summit Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SMMT?

As at 22 Aug 2026, Summit Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).

Will SMMT stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +165.1% from the last close, and Ticker Nerd's factor model ranks Summit Therapeutics, Inc. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SMMT stock forecast for 2030?

No analyst covering Summit Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9.91 to $42 over the next 12 months.

How has SMMT stock performed over the past year?

Summit Therapeutics, Inc. returned -51.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Summit Therapeutics, Inc. do?

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly.

What is the latest news on SMMT?

The most recent item we track (Business Wire, 12 Aug 2026): "Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer". Summit Therapeutics' partner Akeso received marketing authorization from China's NMPA for ivonescimab, a bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.

Company

About Summit Therapeutics, Inc.

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicinal therapies designed to be patient, physician, caregiver, and societally friendly. Its lead candidate, ivonescimab, is a first-in-class bispecific antibody that simultaneously targets PD-1 and VEGF pathways, advancing immunotherapy combined with anti-angiogenesis for oncology applications. The company is conducting multiple Phase III clinical trials evaluating ivonescimab, including in combination with chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) after third-generation TKI therapy, first-line metastatic NSCLC, squamous NSCLC, and first-line unresectable metastatic colorectal cancer. Summit Therapeutics Inc. also pursues collaborations, such as with GSK to combine ivonescimab with investigational therapies in solid tumors including small cell lung cancer. These efforts target serious unmet needs in oncology, particularly lung and colorectal cancers. Founded in 2003 and headquartered in Miami, Florida, Summit Therapeutics Inc. operates in the biotechnology sector with a pipeline centered on next-generation cancer treatments.

CEO Mr. Robert W. Duggan · 265 employees · United States · https://www.smmttx.com